Investigating a new treatment for nicotine addiction in smokers
Official title: Safety/Toxicology, ADME and CMC Activities to Support the Assessment of the mGlu2 PAM SBP-9330 in a Phase 2 Clinical Study in Smokers
Funded at Sanford Burnham Prebys Medical Discovery Institute · NIH-10931623 · Data updated 2026-11-12
This study is testing a new medication called SBP-9330 to see if it can help people quit smoking by working on the brain's nicotine receptors, and it's looking for smokers who want to try this treatment while being closely monitored for safety.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sanford Burnham Prebys Medical Discovery Institute NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | September 30, 2023 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $3,331,239 |
| NIH project number | 5U01DA057847-02 |
| Project ID | NIH-10931623 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adult smokers aged 21 and older who are seeking help to quit smoking.
✕Less likely to help
Patients who do not smoke or are not interested in quitting smoking may not benefit from this research.
What this research studies
This research focuses on assessing the safety and effectiveness of a new drug, SBP-9330, designed to help smokers quit by targeting specific brain receptors involved in nicotine addiction. The study will involve a Phase 2 clinical trial where participants will receive the investigational drug to evaluate its effects on smoking behavior and withdrawal symptoms. The research aims to gather important data on how the drug is absorbed, distributed, metabolized, and excreted in the body, ensuring its safety for smokers. Participants will be monitored for any adverse effects throughout the trial.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment option for individuals struggling with nicotine addiction.
How similar studies have gone: Previous research has shown promise with similar approaches targeting the mGlu2 receptor, indicating potential for success in this area.
Where this research is happening
-
Sanford Burnham Prebys Medical Discovery Institute
La Jolla, United States Active
Researchers
- Principal investigator: Cosford, Nicholas David — Sanford Burnham Prebys Medical Discovery Institute
- Study coordinator: Cosford, Nicholas David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.